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ABSTRACT 
Rifampicin is a naturally made, non-peptide antibiotic. It is bactericidal, killing by disabling the 
protein expression system universally conserved by all bacteria. 1 Specifically, it inhibits the RNA 
polymerase protein, which is responsible for binding to a strand of DNA as a template and using 
it to construct a strand of mRNA. The reason rifampicin works so well is that it is a rigid 
molecule, and sits tightly in the pocket where it binds, allowing the bonds to be very strong. 
However, this also means if an amino acid with the edge of the channel with a small side chain 
is replaced by an amino acid with a large side chain, rifampicin may not be able to bind, simply 
because it cannot fit in the space. Rifampicin is mainly useful in the treatment of tuberculosis 
and meningococcal infections.2, 3,4,5,6  
Coming to the pharmacokinetics of the drug, rifampicin is easily absorbed from the gastro 
intestinal tract. After about six hours almost the entire drug is deacetylated by esterases even 
in this deacytylated form rifampicin is a potent antibiotic. However, it can no longer be 
absorbed by the intestines and it is subsequently eliminated from the body. About 7% of the 
administered drug will be excreted unchanged through the urine, and urinary elimination 
accounts for about 30% of the dose of the drug that is excreted.4, 5,6 
About 60% - 65% is excreted through feces. As a result of this, the drug dose has to be 
increased or the drug must be given at regular intervals to maintain the minimum effective 
concentration. 
Rifampicin shows polymorphism and therefore, it is necessary to select a suitable crystal form 
to ensure optimum solubility and dissolution rates4,5,7.  An increase in amorphous content 
significantly reduces the dissolution rate of the powders in water 8,9. Because of the 
disadvantages both in physical properties and biologically rifampicin has to be synthesized in 
the form of nano particles which have low surface area and show good solubility and 
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dissolution properties. Nano particles can also be designed to allow sustained drug release from 
the matrix. This property of nano particles enables improvement of drug bio-availability and 
reduction of the dosing frequency and may resolve the problem of drug resistance10, which is 
one of the major obstacles in the control of tuberculosis epidemics.  
In this method, equal amounts of PEG200 and tween 60(polysorbate 60) and calculated amount 
of rifampicin was dissolved in that mixture. After that, the solution was stirred with the help of 
high speed magnetic stirrer11. After dissolving the compound completely, this solution was 
added to the water drop wise while the water was stirred with the magnetic stirrer. Then the 
nano particles are formed. If the nano particles are not formed after this procedure, 
homogenizer can be used. After the formation of nanoparticles, characterization using scanning 
electron microscope is done to confirm the surface properties of the nanoparticle. 
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INTRODUCTION 
[12] 
 
Rifampicin is a very popular anti- tubercular drug, effective against Mycobacterium tuberculosis 
[9]. Because of its high bactericidal action, Rifampicin forms a backbone in short-course 
chemotherapy for various forms of TB along with other antibiotics like Isoniazid [9]. As an 
adjuvant, it is used in the treatment of leprosy. On the molecular level, Rifampicin interferes 
with the metabolism of the susceptible bacteria by blocking RNA synthesis [9]. This effect is the 
consequence of the tight binding of the drug to a single and highly specific binding site on the 
DNA-dependent RNA polymerase. The drug-enzyme complex strongly inhibits the initiation of 
RNA chain synthesis not affecting chain elongation [9].  
The treatment of Tuberculosis involves chemotherapy which lasts from 12-18months [9]. 
Proper prescriptions and patient compliance almost always cure. The emergence of drug 
resistant bacteria is the serious concern about this disease [10]. The emergence of strains 
resistant to any of these drugs causes major concern. Multidrug-resistant TB (MDRTB), 
associated with high death rates of 50% to 80%, spans a relatively short time (4 to 16 weeks) 
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from diagnosis to death [10]. Next to the MDRTB, the resistance is attributed primarily to 
improper prescriptions or patient noncompliance [10]. For several months rifampicin must be 
administered daily, if not the drug resistance increases for tuberculosis and is quick too. So 
rifampicin must be used along with other antibiotics. The drug cannot readily inhibit the 
rifampicin resistant bacteria as they produce RNA – polymerase with different beta subunits. 
Rifampicin inhibits DNA – dependent RNA polymerase synthesis by binding to its beta subunit in 
bacteria and therefore preventing transcription and translation to proteins. The lipophilic 
nature of rifampicin makes it to treat meningitis from tuberculosis. Messenger RNA synthesis is 
obstructed by rifampicin. Prokaryotic DNA – primed RNA polymerase mainly gram positive 
stains gets inhibited. The drug moves easily into the cell as the membrane of bacterial cell is 
mycolic acid made up of peptidoglycan. 
Hepatotoxicity is the serious adverse effect when patients are treated with rifampicin, so they 
must undergo liver function tests. Breast feeding must be avoided as it may be excreted 
through milk. Gastro intestinal tract easily absorbs rifampicin and the bile hydrolyzes its ester 
functional group and is catalyzed by high pH enzymes called esterases. It is deacetylated after 
six hours and even in this form rifampicin is potent. Approximately 85% of Rifampicin is 
metabolized by the liver [9], so in order to maintain uniform levels of drug in the body and 
reduce the number of doses attempts encapsulation of this drug into nanoparticles promises a 
good dosage form.  
EXPERIMENTS 
Preparation of nanoparticles: 
Oil/Water:  
Attempt 1: Dissolve Rifampicin (0.03g) in the mixture of Polyethylene Glycol 200 (PEG, 150mL) 
and Tween 60 (0.1459g) using magnetic stirrer. After this take the UV readings using water as 
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blank and solution (0.5mL) with water (1.5mL) as sample. Then the solution was added to water 
(450mL) drop wise using magnetic stirrer. Then take the UV readings using water as blank and 
the solution as sample. There is no color change in the solution since there is unencapsulated 
rifampicin in the final solution. The concentration of rifampicin was too high. 
Attempt 2: Prepare the solution of Tween 60 (0.1529g) and PEG 200 (81mL) using magnetic 
stirrer. This solution was added to the previously prepared solution (150 mL, attempt 1) drop 
wise using magnetic stirrer. There is no color change in the solution. 
Attempt 3: Prepare the solution of Tween 60 (0.1528g) and PEG 200 (81 mL) using magnetic 
stirrer. This solution was added to previously prepared solution (100 mL, attempt 2) drop wise 
using magnetic stirrer. Now the solution is colorless. This solution is sonicated using 
ultrasonicator for 45 minutes. Carbopol ultrez 10NF polymer is added in order to stabilize the 
preparation. This solution is tested for the size of the nanoparticles on Transition Electron 
Microscope (TEM) Phosphotungstic acid (PTA; H3PW12O40) staining method on a copper grid. 
Blank is prepared in the same way without Rifampicin. 
Water/Oil: 
Dissolve Rifampicin (0.0056g) in the mixture of PEG 200 (25 mL) and Tween 60 (0.023g) using 
magnetic stirrer. Water (75mL) was added to the solution drop wise using the magnetic stirrer. 
Then the solution was sonicated using ultrasonicator for 45 minutes. Carbomer interpolymer 
type A is added to stabilize the preparation. 
Blank is prepared in the same way without Rifampicin. 
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Bacterial Study: 
S aureus (gram positive) and E coli (gram negative) are cultured using nutrient broth and 
incubated for 1 day. Then these cultures was transferred to 20 labeled (+ and -) test tubes (8 
mL) and incubated for another day. Then the test tubes are labeled as Dark (D) and light (L) and 
these are differentiated into Oil/Water (O/W), Oil/Water Blank (O/W B), Water/Oil (W/O), 
Water/Oil Blank (W/O B), Control. Add 2 mL of the formulations to respective tubes and 
incubated for 1 hr. The tubes that are marked as D are kept in dark and the other ones are 
irradiated for 90 min. Transfer 10 mL of Trypsin soy broth into the tubes that are labeled as 
before and add 1mL of bacterial culture into the respective tubes. Take 20 petri dishes and label 
them as said above and transfer 3mL of these cultures into the petri dishes (trypsin soy) and 
incubate them at 37°C for 3 days.  
RESULTS 
Nanoparticles: 
The UV reading of the solution without adding water was wavelength, λ-392.47 nm and 
Absorbance, A-1.589 
The UV readings of the final solution was wavelength, λ-475 and Absorbance, A-0.8 
The size of the nanoparticles is in the theoretical range. The following are the images from 
Fluorescence microscopic and TEM images 
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A and B Fluorescent microscopic image of aggregated nanoparticles 
C and D TEM images after sonication  
 
                               
Bacterial Study: 
There is no growth of gram negative (E coli) bacteria for the Light and Dark.  
There is visible growth in gram positive bacteria on O/W and W/O in both L and D. But when 
compared to both W/O has no effect as it does with O/W. 
In order to confirm this effect, this procedure was repeated for 2 times. 
+D W/O has 8470 colonies and +L W/O has 102 colonies.  
The original count was calculated by multiplying the colonies count with dilution factor. 
The first dilution factor was 20 since we took 0.5 mL out of 10 mL. 
B A 
C D 
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The second dilution factor was 400 since we took 20 µL from 8000 µL. 
Culture Plate Tube Original 
+D W/O 8470 28233 1.13*107 
+ L W/O 102 340 1.36*105 
 
The percentage was 12% 
Attempt 1: +D O/W has 207 colonies and +L O/W has 180 colonies 
Culture Plate Tube Original 
+D O/W 207 4140 1.66*106 
+ L O/W 180 3600 1.44*106 
 
The percentage was 86% 
Attempt 2: 1mL of culture on plate 
Culture Plate Tube Original 
+D O/W 71 710 284000 
+ L O/W 98 980 392000 
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The percentage was 72% 
Attempt 3: 1mL of culture on plate 
Culture Plate Tube Original 
+D O/W 191 1910 764000 
+ L O/W 66 660 264000 
 
The percentage was 34.5%. 
By taking the average of the above results (1, 2 and 3), the result was 64.17%. 
DISCUSSION 
We prepared both the types of nanoparticles (O/W and W/O). These solutions were tested for 
the particle size and on bacteria to know which formulation would be best for the maximum 
effect. As seen from the results, there is no effect on the negative bacteria. Even on positive 
bacteria, O/W has maximum effect.  
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